Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma

References

• Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016; 8:421-38; PMID: 27028578; http://dx.doi.org/10.4254/wjh.v8.i9.421
   PubMedGoogle Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118-27; PMID: 21992124; http://dx.doi.org/10.1056/NEJMra1001683
   PubMed Web of Science ®Google Scholar
• Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-801; PMID: 7684822; http://dx.doi.org/10.1056/NEJM199306243282501
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. American J Pathol 2014; 184:574-83; http://dx.doi.org/10.1016/j.ajpath.2013.10.028
   PubMed Web of Science ®Google Scholar
• Choo SP, Tan WL, Goh BK, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer 2016; [Epub ahead of print]; http://dx.doi.org/10.1002/cncr.30237
   Web of Science ®Google Scholar
• Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 4(15 Suppl):14-22; http://dx.doi.org/10.1634/theoncologist.2010-S4-14
   Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID: 18650514; http://dx.doi.org/10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology 2016; 150:835-53; PMID: 26795574; http://dx.doi.org/10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140:1410-26; PMID: 21406195; http://dx.doi.org/10.1053/j.gastro.2011.03.006
   PubMed Web of Science ®Google Scholar
• Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis 2015; 19:421-32; PMID: 25921671; http://dx.doi.org/10.1016/j.cld.2015.01.009
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48:1312-27; PMID: 18821591; http://dx.doi.org/10.1002/hep.22506
   PubMed Web of Science ®Google Scholar
• Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015; 149:1226-39 e4; PMID: 26099527; http://dx.doi.org/10.1053/j.gastro.2015.05.061
   PubMed Web of Science ®Google Scholar
• Monga SP. beta-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. Gastroenterology 2015; 148:1294-310; PMID: 25747274; http://dx.doi.org/10.1053/j.gastro.2015.02.056
   PubMed Web of Science ®Google Scholar
• Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013; 23:1422-33.
   PubMed Web of Science ®Google Scholar
• Delire B, Starkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest 2015; 45:609-23; PMID: 25832714; http://dx.doi.org/10.1111/eci.12441
   PubMed Web of Science ®Google Scholar
• Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol 2014; 60:855-65; PMID: 24308993; http://dx.doi.org/10.1016/j.jhep.2013.11.031
   PubMed Web of Science ®Google Scholar
• Giordano S, Columbano A. Met as a therapeutic target in HCC: facts and hopes. J Hepatol 2014; 60:442-52; PMID: 24045150; http://dx.doi.org/10.1016/j.jhep.2013.09.009
   PubMed Web of Science ®Google Scholar
• Berasain C, Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol 2014; 49:9-23; PMID: 24318021; http://dx.doi.org/10.1007/s00535-013-0907-x
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID: 21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Currie E, Schulze A, Zechner R, Walther TC, Farese RV, Jr. Cellular fatty acid metabolism and cancer. Cell Metab 2013; 18:153-61; PMID: 23791484; http://dx.doi.org/10.1016/j.cmet.2013.05.017
   PubMed Web of Science ®Google Scholar
• Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer 2016; 16:732-49; PMID: 27658529; http://dx.doi.org/10.1038/nrc.2016.89
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7:763-77; PMID: 17882277; http://dx.doi.org/10.1038/nrc2222
   PubMed Web of Science ®Google Scholar
• Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De novo lipogenesis in health and disease. Metabolism 2014; 63:895-902; PMID: 24814684; http://dx.doi.org/10.1016/j.metabol.2014.04.003
   PubMed Web of Science ®Google Scholar
• Herrera E, Amusquivar E. Lipid metabolism in the fetus and the newborn. Diabetes Metab Res Rev 2000; 16:202-10; PMID: 10867720; http://dx.doi.org/10.1002/1520-7560(200005/06)16:3%3c202::AID-DMRR116%3e3.0.CO;2-
   PubMed Web of Science ®Google Scholar
• Khwairakpam AD, Shyamananda MS, Sailo BL, Rathnakaram SR, Padmavathi G, Kotoky J, Kunnumakkara AB. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr Drug Targets 2015; 16:156-63; PMID: 25537655; http://dx.doi.org/10.2174/1389450115666141224125117
   PubMed Web of Science ®Google Scholar
• Peck B, Schulze A. Lipid desaturation - the next step in targeting lipogenesis in cancer? The FEBS J 2016; 283:2767-78; PMID: 26881388; http://dx.doi.org/10.1111/febs.13681
   PubMed Web of Science ®Google Scholar
• Wang C, Ma J, Zhang N, Yang Q, Jin Y, Wang Y. The acetyl-CoA carboxylase enzyme: a target for cancer therapy? Expert Rev Anticancer Ther 2015; 15:667-76; http://dx.doi.org/10.1586/14737140.2015.1038246
   PubMed Web of Science ®Google Scholar
• Lamming DW, Sabatini DM. A Central role for mTOR in lipid homeostasis. Cell Metab 2013; 18:465-9; PMID: 23973332; http://dx.doi.org/10.1016/j.cmet.2013.08.002
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID: 22500797; http://dx.doi.org/10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab 2012; 16:414-9; PMID: 23000402; http://dx.doi.org/10.1016/j.cmet.2012.09.002
   PubMed Web of Science ®Google Scholar
• Hao Q, Li T, Zhang X, Gao P, Qiao P, Li S, Geng Z. Expression and roles of fatty acid synthase in hepatocellular carcinoma. Oncol Rep 2014; 32:2471-6; PMID: 25231933
   PubMed Web of Science ®Google Scholar
• Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman KE, Wooster R, Kang J, Qin CY. Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma. Int J Mol Sci 2012; 13:9980-91; PMID: 22949843; http://dx.doi.org/10.3390/ijms13089980
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011; 140:1071-83; PMID: 21147110; http://dx.doi.org/10.1053/j.gastro.2010.12.006
   PubMed Web of Science ®Google Scholar
• Ono H, Shimano H, Katagiri H, Yahagi N, Sakoda H, Onishi Y, Anai M, Ogihara T, Fujishiro M, Viana AY, et al. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 2003; 52:2905-13; PMID: 14633850; http://dx.doi.org/10.2337/diabetes.52.12.2905
   PubMed Web of Science ®Google Scholar
• Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 2004; 101:2082-7; PMID: 14769918; http://dx.doi.org/10.1073/pnas.0308617100
   PubMed Web of Science ®Google Scholar
• Gao Y, Lin LP, Zhu CH, Chen Y, Hou YT, Ding J. Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther 2006; 5:978-85; PMID: 16855382; http://dx.doi.org/10.4161/cbt.5.8.2883
   PubMed Web of Science ®Google Scholar
• Li L, Pilo GM, Li X, Cigliano A, Latte G, Che L, Joseph C, Mela M, Wang C, Jiang L, et al. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J Hepatol 2016; 64:333-41; PMID: 26476289; http://dx.doi.org/10.1016/j.jhep.2015.10.004
   PubMed Web of Science ®Google Scholar
• Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. The J Biol Chem 1999; 274:30028-32; PMID: 10514488; http://dx.doi.org/10.1074/jbc.274.42.30028
   PubMed Web of Science ®Google Scholar
• Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. “New” hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 2005; 1:309-22; PMID: 16054078; http://dx.doi.org/10.1016/j.cmet.2005.04.002
   PubMed Web of Science ®Google Scholar
• Hu J, Che L, Li L, Pilo MG, Cigliano A, Ribback S, Li X, Latte G, Mela M, Evert M, et al. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Sci Rep 2016; 6:20484.
   PubMed Web of Science ®Google Scholar
• Tao J, Xu E, Zhao Y, Singh S, Li X, Couchy G, Chen X, Zucman-Rossi J, Chikina M, Monga SP. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant beta-catenin. Hepatology 2016; 64:1587-605; PMID: 27097116; http://dx.doi.org/10.1002/hep.28601
   PubMed Web of Science ®Google Scholar
• Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 2013; 52:585-9; PMID: 24001676; http://dx.doi.org/10.1016/j.plipres.2013.08.005
   PubMed Web of Science ®Google Scholar
• Goldberg IJ, Eckel RH, Abumrad NA. Regulation of fatty acid uptake into tissues: lipoprotein lipase- and CD36-mediated pathways. J Lipid Res 2009; (50 Suppl):S86-90; PMID: 19033209
   PubMedGoogle Scholar
• Cao D, Song X, Che L, Li X, Pilo MG, Vidili G, Porcu A, Solinas A, Cigliano A, Pes GM, et al. Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver Int 2016; 37(1):80-89; PMID: 27264722; http://dx.doi.org/10.1111/liv.13183
   PubMed Web of Science ®Google Scholar
• Augustus A, Yagyu H, Haemmerle G, Bensadoun A, Vikramadithyan RK, Park SY, Kim JK, Zechner R, Goldberg IJ. Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. J Biol Chem 2004; 279:25050-7; PMID: 15028738; http://dx.doi.org/10.1074/jbc.M401028200
   PubMed Web of Science ®Google Scholar
• Jones SF, Infante JR. Molecular Pathways: Fatty Acid Synthase. Clinical cancer research : an official journal of the American Association for Cancer Res 2015; 21:5434-8; http://dx.doi.org/10.1158/1078-0432.CCR-15-0126
   PubMed Web of Science ®Google Scholar
• Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010; 6:551-62; PMID: 20373869; http://dx.doi.org/10.2217/fon.10.11
   PubMed Web of Science ®Google Scholar
• Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000; 60:213-8; PMID: 10667561
   PubMed Web of Science ®Google Scholar
• Relat J, Blancafort A, Oliveras G, Cufi S, Haro D, Marrero PF, Puig T. Different fatty acid metabolism effects of (−)-epigallocatechin-3 gallate and C75 in adenocarcinoma lung cancer. BMC Cancer 2012; 12:280; PMID: 22769244; http://dx.doi.org/10.1186/1471-2407-12-280
   PubMed Web of Science ®Google Scholar
• Chen HW, Chang YF, Chuang HY, Tai WT, Hwang JJ. Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model. Prostate Cancer Prostatic Dis 2012; 15:260-4; PMID: 22565411; http://dx.doi.org/10.1038/pcan.2012.15
   PubMed Web of Science ®Google Scholar
• Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M. Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells. J Urol 2008; 180:729-36; PMID: 18555493; http://dx.doi.org/10.1016/j.juro.2008.03.186
   PubMed Web of Science ®Google Scholar
• Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2005; 24:39-46; PMID: 15489885; http://dx.doi.org/10.1038/sj.onc.1208174
   PubMed Web of Science ®Google Scholar
• Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A, Vera L, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med 2016; 22:1108-19; PMID: 27643638; http://dx.doi.org/10.1038/nm.4181
   PubMed Web of Science ®Google Scholar
• Nie B, Park HM, Kazantzis M, Lin M, Henkin A, Ng S, Song S, Chen Y, Tran H, Lai R, et al. Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology 2012; 56:1300-10; PMID: 22531947; http://dx.doi.org/10.1002/hep.25797
   PubMed Web of Science ®Google Scholar
• Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A 2007; 104:14771-6; PMID: 17785413; http://dx.doi.org/10.1073/pnas.0706578104
   PubMed Web of Science ®Google Scholar
• Li L, Che L, Tharp KM, Park HM, Pilo MG, Cao D, Cigliano A, Latte G, Xu Z, Ribback S, et al. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology 2016; 63:1900-13; PMID: 26910791; http://dx.doi.org/10.1002/hep.28508
   PubMed Web of Science ®Google Scholar
• Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol 2014; 184:912-23; PMID: 24480331; http://dx.doi.org/10.1016/j.ajpath.2013.12.002
   PubMed Web of Science ®Google Scholar